Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nanoxel®M in BCG-refractory NMIBC
NCT02982395Phase 3Terminated
- Sponsor
- Samyang Biopharmaceuticals Corporation
- Start
- Jan 2017
- Primary completion
- Aug 2018
- Modality
- Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of Nanoxel M in non-muscle-invasive bladder cancer (NMIBC) (2 arms), sponsored by Samyang Biopharmaceuticals Corporation. Primary endpoint: Recurrence Free Rate at 1 year. Started Jan 2017; status: terminated.
02
Drugs
Nanoxel M
03
Conditions
non-muscle-invasive bladder cancer (NMIBC)
Beyond the preview
Go deeper on NCT02982395.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02982395.